1-4 of 4
Giri Ramsingh
Close
Sort by
Journal Articles

Nature of Clinical Response and Depth of Molecular Response in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Treated with Magrolimab with Azacitidine

Lisa Johnson, Yajia Zhang, Biao Li, Lisa Aviles, Indu Lal, Giri Ramsingh, Naval Daver, Paresh Vyas, David A. Sallman
Journal: Blood
Blood (2022) 140 (Supplement 1): 6934–6935.
https://doi.org/10.1182/blood-2022-160337
Published: 2022
Journal Articles

Clinical Characteristics and Overall Survival Among Acute Myeloid Leukemia (AML) Patients with TP53 Gene Mutation (TP53m) or Chromosome 17p Deletion (17p del)

Naval Daver, Shahed Iqbal, Julie Huang, Camille Renard, Joyce Lin, Harry Pan, Guan Xing, Yang Pan, Giri Ramsingh
Journal: Blood
Blood (2022) 140 (Supplement 1): 1445–1446.
https://doi.org/10.1182/blood-2022-170298
Published: 2022
Journal Articles

A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine in Previously Untreated Patients with TP53 -Mutant Acute Myeloid Leukemia

Naval Daver, Paresh Vyas, Mark Chao, Guan Xing, Camille Renard, Giri Ramsingh, David A. Sallman, Andrew H. Wei
Journal: Blood
Blood (2021) 138 (Supplement 1): 3426.
https://doi.org/10.1182/blood-2021-145208
Published: 2021
Journal Articles

A Phase 2, Open-Label, Multiarm, Multicenter Study to Evaluate Magrolimab Combined with Antileukemia Therapies for First-Line, Relapsed/Refractory, or Maintenance Treatment of Acute Myeloid Leukemia

Paresh Vyas, Naval Daver, Mark Chao, Guan Xing, Camille Renard, Giri Ramsingh, Andrew H. Wei, David A. Sallman
Journal: Blood
Blood (2021) 138 (Supplement 1): 3424.
https://doi.org/10.1182/blood-2021-145584
Published: 2021